1148. Relationship Between the Duration of Symptoms Before and COVID-19 Disease Outcome After Monoclonal Antibody Therapy

BACKGROUND: Clinical trials of monoclonal antibodies therapy (MAB) for COVID-19 demonstrated the risk reduction of COVID related hospitalization and death of any cause if administered within the first 7 days from the symptom onset. The Food and Drug Administration (FDA) issued an emergency use autho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hubbard, Michael J, Polega, James, Haggerty, Diana K, Andersen, Nicholas A, Simeunovic, Gordana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752680/
http://dx.doi.org/10.1093/ofid/ofac492.986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752680/
http://dx.doi.org/10.1093/ofid/ofac492.986

Ejemplares similares